natgillin/translations-raw huggingface dataset:
Stevens-Johnsons syndrom†, erythema multiforme†, bulløs dermatitis†
Stevens-Johnson syndrome†, Erythema multiforme†, Dermatitis bullous
Stevens-Johnsons-syndrom (sjældent; < 0,1 %) og toksisk epidermal nekrolyse (meget sjældent; < 0,01 %) blev rapporteret under den kliniske udvikling af INTELENCE.
Stevens-Johnson Syndrome (rare; < 0.1%) and toxic epidermal necrolysis (very rare; < 0.01%) have been reported during clinical development with INTELENCE.
stige på grund af Kaletras
increased due to CYP3A
Stigende alder kan øge blødningsrisikoen (se pkt.
Increasing age may increase haemorrhagic risk (see section 5.2).
Stigende leverenzymer
Hepatic enzymes increased
Stigning
Increase
Stigning af leverenzymer, svimmelhed, søvnløshed, konfusion, følelse af at være forpustet, opkastning (med eller uden blod), forstoppelse, blod i urinen, vandladningsbesvær, udslæt, kløe (urtikaria), lavt indhold af kalium i blodet, brændende fornemmelse ved vandladning sammen med en øget vandladningshyppighed, langsom sårheling, næseblod, højt blodtryk, smerter (herunder smerter i benene, maven og/eller brystet).
Increase in liver enzymes, dizziness, sleeplessness, confusion, feeling breathless, vomiting (with or without blood), constipation, blood in your urine, difficulty in urinating, rash, itching (urticaria), low levels of potassium in the blood, burning feeling when passing urine with also an increased frequency of urination, slow healing of wounds, nose bleeds, high blood pressure, pain (including pain in legs, stomach and/or chest).
Stigning af visse enzymer i blodet
increase of certain enzymes in the blood
Stigning anses ikke for
Increase not thought to be clinically
Stigning anses ikke for
increase the potential for acute ergot
Stigning anses ikke for at være klinisk relevant.
clinical monitoring and appropriate
Stigning fra baseline i serum-kreatinin på grund af cobicistat alene overstiger generelt ikke 0,4 mg/dl.
An increase from baseline in serum creatinine solely due to cobicistat’s inhibitory effect generally does not exceed 0.4 mg/dl.
Stigning fra baseline i serum-kreatinin på grund af cobicistat alene, overstiger generelt ikke 0,4 mg/dl.
An increase from baseline in serum creatinine solely due to cobicistat’s inhibitory effect generally does not exceed 0.4 mg/dl.
Stigning i alanin- aminotransferase
Alanine aminotransferase increased
Stigning i alanin- aminotransferase (ALAT)
Increased alanine transaminase (ALT)
Stigning i alaninaminotransferase, stigning i aspartataminotransferase
Alanine aminotransferase increased, aspartate aminotransferase increased
Stigning i ALAT
ALT increased
Stigning i aminotransferase (forhøjet alaninaminotransferase, forhøjet aspartataminotransferase, forhøjet gammaglutamyltransferase, forhøjet leverenzym, unormal leverfunktion, unormal leverfunktionstest, forhøjede aminotransferaser).
Elevated transaminases (Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma- glutamyltransferase increased, Hepatic enzyme increased, Hepatic function abnormal, Liver function test abnormal, Transaminases increased).
Stigning i aminotransferase r
Increase in transaminases
Stigning i amylase
Amylase increased
Stigning i amylase, som er et enzym, der findes i spytkirtlerne og bugspytkirtlen, forhøjet urinkvælstof i blodet
Increase in amylase, which is an enzyme found in the salivary glands and pancreas, increased blood urea nitrogen (BUN).
Stigning i antal blodplader
Increase in platelet count
Stigning i antallet af blodplader
Increase in platelet count
stigning i antallet af nogle enzymer, der dannes i leveren  kan ses i blodprøver
increase in the amount of some enzymes produced by your liver - shown in blood tests
Stigning i antallet af små blodceller (trombocytter), som normalt medvirker i dannelsen af en blodprop.
Increased levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur.
Stigning i ASAT (c)
AST increase (c)
Stigning i ASAT, øget alkalisk fosfatase i blodet
AST increased, blood alkaline phosphatase increased
Stigning i aspartat- aminotransferase
Aspartate aminotransferase increased
Stigning i AUC, Cmax og Tmax for nelfinavir efter indtagelse af føde med lavt fedtindhold (20 %) versus højt fedtindhold (50 %) i forhold til fastende tilstand efter 1250 mg VIRACEPT (5 x 250 mg tabletter)
Increase in Nelfinavir AUC, Cmax and Tmax in Fed Low Fat (20%) versus High fat (50%) State Relative to Fasted State Following 1250 mg VIRACEPT (5 x 250 mg tablets)
Stigning i basisk fosfatase
Alkaline phosphatase increased
Stigning i blodglucose
Blood glucose increased
Stigning i blodkreatinin
Blood creatinine increased
Stigning i blodkreatinin a, d
Increase in blood creatinine a, d
stigning i blodkreatininniveauer, som kan ses i en laboratorietest, der viser hvor godt dine nyrer fungerer blodprøver, der viser en stigning i størrelsen af røde blodlegemer.
increase in blood creatinine levels seen from a laboratory test showing how well your kidneys are working blood test showing increase of red blood cell size.
Stigning i blodprøve til bestemmelse af leverfunktion
An increase in blood test results that show how your liver is working
Stigning i blodprøve til bestemmelse af leverfunktion
An increase in blood test results that show how your liver is working.
Stigning i blodsukker
Increase in blood glucose
Stigning i blodtryk
increase in blood pressure
Stigning i C-reaktivt protein
C-reactive protein increased
Stigning i Cmax
Cmax fold increase
Stigning i faktor X-niveau (IE/dl eller % af det normale) = [total dosis (IE)/legemsvægt (kg)] x 2
Increase in factor X level (IU/dL or % of normal) = [total dose (IU)/body weight (kg)] x 2
Stigning i gamma- glutamyltransferase
Increase in gamma-glutamyl transferase
Stigning i gamma-glutamyltransferase
Gamma-glutamyltransferase increase
Stigning i GGT (c)
GGT increase (c)
Stigning i infusionshastighed
Increments of infusion rate
Stigning i insulinantistoffer
Increased insulin antibody levels
Stigning i international normaliseret ratio (se pkt.
International normalised ratio increased (see section 4.4)
Stigning i intraokulært tryk
Intraocular pressure increases
Stigning i kolesterol og triglycerider
Increases in cholesterol and triglycerides
Stigning i konjungeret bilirubin (med eller uden samtidig stigning i ALAT)
Bilirubin conjugated increased (with or without concomitant increase of ALT)
Stigning i kreatinin
Creatinine increased
Stigning i kreatinin bør ikke nødvendigvis føre til seponering af ACE-hæmmere eller angiotensin II- receptorantagonister (AIIRAer).
An increase in creatininemia should not necessarily lead to the discontinuation of treatment with ACE inhibitors or Angiotensin II Receptors Antagonists (AIIRAs).
Stigning i kreatininniveau i blodet,
Increase in creatinine level in the blood,
Stigning i kreatinkinase
Creatine phosphokinase (CPK) elevations
Stigning i kreatinkinase
Elevations in creatine kinase
stigning i kreatinkinase, et enzym, der hovedsageligt findes i hjertet, hjernen og skeletmuskulaturen
Increase in creatine phosphokinase, an enzyme found mainly in heart, brain, and skeletal muscle
stigning i kropstemperatur (feber)
increases in body temperature (fever)
Stigning i LDL-kolesterol til > 1,5 til 2 gange øvre normalgrænse forekom hos 1,9 % af patienterne i tocilizumab-gruppen og hos 0 % i placebogruppen.
Elevation in LDL > 1.5 x ULN to 2 x ULN occurred in 1.9% of patients in the tocilizumab group, and in 0% of the placebo group.
Stigning i legemesvægt2
Bodyweight gain2
Stigning i legemstemperatur på mere end 2,5 °C, der varer under 24 timer, ses sjældent.
Rarely , an increase in rectal temperature of higher than 2.5 °C, lasting less than 24 hours, may occur.
Stigning i leverenzymer
Hepatic enzyme increase
Stigning i leverenzymer
Increase in liver enzymes
Stigning i leverenzymer
Liver enzyme increased
Stigning i leverenzymer (c)
Hepatic enzyme increase (c)
Stigning i leverenzymer til > 3 x ULN
Increase in hepatic enzymes to > 3 × ULN
Stigning i leverenzymtal
Increase in liver enzymes
Stigning i lipase
Lipase increased
Stigning i middel- AUC er lineær og proportional med dosis i det terapeutiske område.
The increase in mean AUC is linear and dose proportional in the therapeutic range.
Stigning i middelcellevolumen, fald i neutrofiler
increases in MCV, decreases in neutrophils
Stigning i niveauerne af leverenzymer (GGT, ASAT og ALAT)
Increase in liver enzymes (GGT, AST and ALT).
Stigning i niveauet af blodsukkeret (hyperglykæmi)
Increase in blood sugar levels (hyperglycemia).
stigning i nogle stoffer (enzymer), som produceres af leveren
Increase in some substances (enzymes) produced by the liver
Stigning i plasmakreatinin*
Blood creatinine increased
Stigning i prandial blodglucose 90 minutter efter doseringsmåltid (plasma) (mmol/l)
Prandial Blood-glucose Increment 90 minutes after dosing meal (Plasma) (mmol/l)
Stigning i protrombintid (PT) (ved samtidig behandling med vitamin K- antagonist).
Prothrombin time (PT) increase (with concomitant vitamin K antagonist therapy).
Stigning i reticulocyttal til
Reticulocyte count increase
Stigning i reticulocyttal til  40.000/mikroliter
Reticulocyte count increase  40,000/µl
Stigning i retikulocyttal til ≥ 40 000/mikroliter eller stigning i Hb med ≥ 1 g/dl
Reticulocyte count increase ≥ 40 000/μl or Hb increase ≥ 1 g/dl
Stigning i thyroideastimulerende hormon
Blood thyroid stimulating hormone increased
Stigning i Tmax (timer)
Increase in Tmax (hr)
Stigning i transaminaser
Increase in transaminases
Stigning i transaminaser, stigning i aspartat-aminotransferase, stigning i gamma-glutamyltransferase, abnorme leverfunktionsprøver, stigning i basisk phosphatase, forhøjet bilirubin i blodet
Transaminases increased, aspartate aminotransferase increased, gamma- glutamyltransferase increased, liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased
Stigning i triglycerider (en type fedt i blodet), ændringer i kropsform på grund af fedtomfordeling.
Increases in triglycerides (a type of blood fat), changes in body shape because of fat redistribution,
Stigning i visse enzymer i blodet
increase of certain enzymes in the blood
Stigningb
Increaseb
Stigningen i andelen af patienter, der opnåede SVR, var overensstemmende på tværs af alle undergrupper i de randomiserede strata (baseline trombocyttal (< 50.000 vs. > 50.000), virusbelastning (< 800.000 IE/ml vs. ≥ 800.000 IE/ml) og genotype (2/3 vs.
The improvement in the proportion of patients who achieved SVR was consistent across all subgroups in the randomisation strata (baseline platelet counts (< 50,000 vs. > 50,000), viral load (< 800,000 IU/ml vs. ≥ 800,000 IU/ml) and genotype (2/3 vs.
Stigningen i AUC∞, AUCt og Cmax ligger på henholdsvis 111,88 %, 114,06 % og 115,28 %.
The increase in AUC∞, AUCt, and Cmax is of 111.88%, 114.06%, and 115.28% respectively.
Stigningen i efavirenz'
Efavirenz:
Stigningen i levertumorer ved administration af presugrel til mus betragtes ikke som en relevant human risiko.
The increase in liver tumours with prasugrel administration in mice is not considered a relevant human risk.
Stigningen i middel- AUC er lineær og proportional med dosis i det terapeutiske område.
The increase in mean AUC is linear and dose proportional in the therapeutic range.
Stigningen i middel-AUC er lineær og dosisproportional i det terapeutiske område.
The increase in mean AUC is linear and dose proportional in the therapeutic range.
Stigningen i overlevelse i armen, hvor docetaxel blev indgivet ugentlig, var ikke statistisk signifikant sammenlignet med kontrolarmen for mitoxantron.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Stigningen i overlevelse set i armen med ugentlig docetaxel var ikke statistisk signifikant sammenlignet med kontrolarmen på mitoxantron.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Stigningen i overlevelse set i armen med ugentlig docetaxel var ikke statistisk signifikant sammenlignet med mitoxantron-kontrol-armen.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Stigningen i overlevelse set i armen med ugentlig docetaxel var ikke statistisk signifikant sammenlignet med mitoxantron-kontrolarmen.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Stigningen i overlevelse set i armen med ugentlig docetaxel var ikke statistisk signifikant sammenlignet med mitxantron kontrol-armen.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Stigningen i plasmakoncentrationer havde en stærk korrelation med en stigning i afsluttende elimineringshalveringstider.
The increase in plasma concentrations was strongly correlated with an increase in terminal elimination half-lives.
Stigningen i steady- state-RBC-koncentrationerne fra stof-relateret materiale, som ikke hæmmede aktiviteten fra RBC- karboanhydrase til niveauer, som var forbundne med systemiske bivirkninger.
This increase in steady-state RBC concentrations of substance-related material did not inhibit RBC carbonic anhydrase activity to levels that are associated with systemic side effects.
Stigningen i urinmængden hos forsøgspersoner med type 2-diabetes mellitus, som blev behandlet med dapagliflozin 10 mg, var vedvarende efter 12 uger og androg ca.
Urinary volume increases in subjects with type 2 diabetes mellitus treated with dapagliflozin 10 mg were sustained at 12 weeks and amounted to approximately 375 ml/day.
Stigningen var statistisk signifikant i dette studie (p=0,022).
The increase was statistically significant in this study (p=0.022).
Stigninger i aktiviteten af leverenzymer forbundet med kliniske tegn på anoreksi, apati eller opkastning var ualmindeligt.
Increases in liver enzyme activities associated with clinical signs of anorexia, apathy or vomiting were uncommon.
Stigninger i ALAT (se afsnit 4.4)
ALT elevations (see section 4.4)
Stigninger i ALAT (se pkt.
ALT elevations (see section 4.4)
Stigninger i aminotransferaser
Transaminase elevations
Stigninger i aminotransferaser blev associeret med forhøjet bilirubin (> 2 x ULN) uden tegn på biliær obstruktion hos 0,2% (5) af patienterne på bosentan og hos 0,3% (6) af patienterne på placebo.
Elevations in aminotransferases were associated with elevated bilirubin ( 2  ULN) without evidence of biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.
Stigninger i aminotransferaser blev associeret med forhøjet bilirubin (>2 x ULN) uden tegn på biliær obstruktion hos 0,2% (5) af patienterne på bosentan og hos 0,3% (6) af patienterne på placebo.
Elevations in aminotransferases were associated with elevated bilirubin ( 2  ULN) without evidence of biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.
Stigninger i ASAT og ALAT eller total–bilirubin bør vurderes for at udelukke andre årsager til leverskade, som f.eks. infektioner, tumorprogression eller samtidig medicinering og bør monitoreres indtil remission/ophør.
Increases in AST and ALT or total bilirubin should be evaluated to exclude other causes of hepatic injury, including infections, tumour progression, or concomitant medication and monitored until resolution.
Stigninger i fedtindholdet i blodet (triglycerider)
Increases in your triglyceride levels (fatty substances in the blood)
Stigninger i fedtstoffer i blodet
Increases in blood lipids
Stigninger i forekomsten af serumtransaminaser bør føre til nøje monitorering og undersøgelse.
The occurrence of elevations in serum transaminases should lead to close monitoring and investigation.
Stigninger i hyppigheden af visse bivirkninger (herunder smerte ved administrationsstedet, rødme og feber) efter anden dosis til børn under 6 år blev observeret i andre kliniske studier, hvor børn fra 6 måneder til 17 år fik en anden pandemisk influenzavaccine (H5N1 A/Indonesien/05/2005 fremstillet i Dresden, Tyskland).
In other clinical studies where children 6 months to 17 years received another pandemic influenza vaccine (H5N1 A/Indonesia/05/2005 manufactured in Dresden, Germany), increases in the frequency of some side effects (including injection site pain, redness and fever) were seen after the second dose in children aged less than 6 years.
Stigninger i hyppigheden af visse bivirkninger (herunder smerte ved injektionsstedet, rødme og feber) hos børn under 6 år blev set i andre kliniske studier, hvor børn fra 6 måneder til 17 år fik Prepandrix.
In other clinical studies where children 6 months to 17 years received Prepandrix, increases in the frequency of some side effects (including injection site pain, redness and fever) were seen after the second dose in children aged less than 6 years.
Stigninger i kromosomafvigelser blev observeret i de perifere lymfocytter hos leukæmipatienter, hos patienter med renalcellecarcinom, som fik en ikke defineret dosis 6–mercaptopurin, og hos patienter med kronisk nyresygdom behandlet med doser på 0,4 – 1,0 mg/kg/dag.
Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6–mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 – 1.0 mg/kg/day.
Stigninger i leveraminotransferase
Hepatic transaminase elevations
Stigninger i leveraminotransferaser (ASAT, ALAT) er blevet forbundet med PAH og med endothelinreceptorantagonister (ERA’er).
Elevations of liver aminotransferases (AST, ALT) have been associated with PAH and with endothelin receptor antagonists (ERAs).
Stigninger i leverenzymer (fundet ved rutinemæssig undersøgelser af leverfunktionen)
Increases in liver enzymes (identified in routine liver function testing)
Stigninger i leverenzymer > 10xULN
Increase in hepatic enzymes >10x ULN
Stigninger i nyrefunktionstest
Increases in test for kidney function
Stigningerne i BMD i total-hofte var henholdsvis 0,3; 1,9 og 3,0 % for de 3 behandlingsgrupper.
Increases in BMD at the total hip were 0.3, 1.9, and 3.0 for the 3 groups, respectively.
Stigningerne i kreatinin >50 % var mere udtalte hos patienter over 75 år (ticagrelor 13,6 % versus clopidogrel 8,8 %.), hos patienter med svært nedsat nyrefunktion ved baseline (ticagrelor 17,8 % versus clopidogrel 12,5 %) og hos patienter, der var i samtidig behandling med antiogensin II-receptorantagonist (ticagrelor 11,2 % versus clopidogrel 7,1 %).
Creatinine elevations by >50% were more pronounced in patients > 75 years (ticagrelor 13.6% versus clopidogrel 8.8%), in patients with severe renal impairment at baseline (ticagrelor 17.8% versus clopidogrel 12.5%) and in patients receiving concomitant treatment with ARBs (ticagrelor 11.2% versus clopidogrel 7.1%).
Stigningerne i kreatininniveauet var sammenlignelige med adskillige baggrundsregimer.
Creatinine increases were comparable by various background regimens.
Stigningerne i lipaseaktiviteten var forbigående og var sædvanligvis ikke ledsaget af tegn eller symptomer på pankreatitis hos forsøgspersoner med forskellige solide tumorer.
Increases in lipase activities were transient and were generally not accompanied by signs or symptoms of pancreatitis in subjects with various solid tumours.
Stigningerne i lipidparametrene responderede på behandling med lipidsænkende midler.
Elevations in lipid parameters responded to treatment with lipid-lowering agents.
Stigningerne i simvastatin- og simvastatinsyreeksponering betragtes ikke som klinisk relevante.
The increase in simvastatin and simvastatin acid exposures are not considered clinically relevant.
Stigningerne var hverken ledsaget af klinisk relevante stigninger i bilirubin eller af kliniske symptomer på hepatitis eller leverinsufficiens.
These elevations were not associated with clinically relevant increase in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic impairment.
Stigningerne var hverken ledsaget af klinisk relevante stigninger i bilirubin eller af kliniske symptomer på hepatitis eller nedsat leverfunktion.
These elevations were not associated with clinically relevant increase in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic impairment.
Stigningsraten for hæmoglobin > 2 g/dl over en 4 ugers periode.
The rate of increase of haemoglobin > 2 g/dl in any 4 week period.
Stigningsraten for hæmoglobin ligger under 0,7 g/dl over en 4 ugers periode.
The rate of increase of haemoglobin is below 0.7 g/dl in any 4 week period.
Stik applikatoren (C) godt ned i tilpasningsstykket.
Insert the applicator (C) firmly into the adapter.
Stik den gule kanyle gennem midten af gummiproppen på hætteglasset.
Push the yellow needle through the centre of the rubber stopper of the vial.
Stik hele kanylen ind i hudfolden i en 90 graders vinkel.
Insert the entire needle at an angle of 90 degrees into the fold of the skin
Stik hele nålen ind i hudfolden.
Insert the full length of the needle into the skin fold
Stik herefter nålen ind i hætteglasset med langtidsvirkende insulin, vend hætteglasset og sprøjten på hovedet, og træk den ordinerede dosis ind i sprøjten.
Push the needle into the vial of long–acting insulin, turn the vial and syringe upside down and draw out the dose you have been prescribed.
Stik hurtigt kanylen lige i hudfolden, indtil kanylen er trængt helt ind under huden (se figur I).
Quickly insert the needle straight into the skin fold until the needle is fully under the skin. (See Figure I.)
STIK IND
INSERT
Stik injektionskanylen gennem huden og ind i musklen med et hurtig dart-lignende indstik i en vinkel på 90 o.
Insert the injection needle with a quick dart-like thrust at right angles to the skin, into the muscle.
Stik kanylen gennem gummihætten på toppen af hætteglasset med Pegasys (3).
Insert the needle through the rubber top of the Pegasys vial (3).
Stik kanylen helt i bund i den sammenklemte hud.
Insert the needle to its full depth into the pinched skin.
Stik kanylen helt ind i den sammenklemte hud i en vinkel på 45° til 90° (6).
Insert the needle all the way into the pinched skin at an angle of 45 to 90 (6).
Stik kanylen helt ind i den sammenklemte hud i en vinkel på 45° til 90 (6).
Insert the needle all the way into the pinched skin at an angle of 45 to 90 (6).
Stik kanylen helt ind i huden, som Deres læge eller sygeplejerske har vist det.
Put the needle fully into the skin as shown by your nurse or doctor.
Stik kanylen helt ind i huden, som Deres læge, sygeplejerske eller farmaceut har vist Dem.
Insert the needle fully into the skin as shown by your doctor, nurse or pharmacist.
Stik kanylen helt ind i huden, som sygeplejersken eller lægen har vist dig (se billede 6).
Put the needle fully into the skin as shown by your nurse or doctor (see picture 6).
Stik kanylen i hudfolden i en vinkel på 45° til 90° med en hurtig, fast bevægelse (se Fig.
Insert the needle all the way into the pinched skin at an angle between 45° to 90° with a quick, firm action. (See Fig.
Stik kanylen ind i den sammenklemte hud i en vinkel på 45 til 90.
Insert the needle into the pinched skin at an angle of 45 to 90.
Stik kanylen ind i den sammenklemte hud med en vinkel på cirka 45.
Insert the needle into the pinched skin at an angle of approximately 45°.
Stik kanylen ind i den sammenklemte hud med en vinkel på cirka 45.
Insert the needle into the pinched skin at an angle of approximately 45.
Stik kanylen ind i huden, som anvist af din læge.
Insert the needle into the skin as you have been told by your doctor.
Stik kanylen ind i huden, som anvist af din læge.
Place RebiSmart at a right angle (90°) to the skin.
STIK kanylen ind i huden.
INSERT needle into skin.
Stik kanylen ind i huden.
Insert the needle into the skin.
Stik kanylen ind i hætteglasset og træk et passende volumen opløsning op i sprøjten.
Insert the needle into the vial and withdraw into the syringe an appropriate volume of solution.
Stik kanylen ind i venen, og fastgør venepunktursættet med et plaster.
Puncture the vein and secure the venipuncture set with a plaster.